Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

10.00 -0.22 (-2.15%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,050,633
Open	10.22
Bid (Size)	9.820 (500)
Ask (Size)	10.00 (200)
Prev. Close	10.22
Today's Range	9.940 - 10.43
52wk Range	4.155 - 11.66
Shares Outstanding	133,976,538
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

7 Bull Flag Setups Found With the ChartMill Stock Screener ↗

April 28, 2026

Via Chartmill

Vir Biotechnology (VIR) CEO Sells 73,000 Shares for $664,000 ↗

April 12, 2026

Focused on infectious disease therapies, this biotech firm reported a notable insider sale amid a year of strong share price gains.

Via The Motley Fool

Performance

YTD	+68.4%	+68.4%
1 Month	+10.4%	+10.4%
3 Month	+29.7%	+29.7%
6 Month	+78.6%	+78.6%
1 Year	+62.3%	+62.3%

More News

VIR Biotechnology Inc (NASDAQ:VIR) Emerges as a High-Growth Momentum Pick ↗

April 07, 2026

Via Chartmill

Unusual volume stocks are being observed in Monday's session. ↗

March 02, 2026

Via Chartmill

Vir Biotechnology to Participate in Upcoming Investor Conferences

February 26, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Get insights into the top gainers and losers of Thursday's pre-market session. ↗

February 26, 2026

Via Chartmill

Vir Biotechnology Inc (NASDAQ:VIR) Reports Q4 2025 Revenue Beat and Major Pipeline Updates ↗

February 23, 2026

Via Chartmill

Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown ↗

November 09, 2025

Via Stocktwits

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

February 25, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces Proposed Public Offering of Common Stock

February 24, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Tuesday's session: top gainers and losers ↗

February 24, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

February 24, 2026

Via Chartmill

Which stocks are moving before the opening bell on Tuesday? ↗

February 24, 2026

Via Chartmill

VIR Stock Surges 60% Pre-Market Today – Analysts Cheer Strong Cancer Data, Astellas Partnership ↗

February 24, 2026

Via Stocktwits

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today? ↗

February 23, 2026

Via Stocktwits

Vir Biotechnology (VIR) Earnings Call Transcript ↗

February 23, 2026

Via The Motley Fool

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer

February 23, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Host Conference Call for Fourth Quarter and Full Year 2025 Financial Results

February 09, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

January 12, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

December 16, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Is Alnylam Pharmaceuticals a Millionaire Maker? ↗

December 07, 2025

Via The Motley Fool

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

November 19, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

November 09, 2025

From Vir Biotechnology, Inc.

Via Business Wire

Frequently Asked Questions

Is Vir Biotechnology, Inc. - Common Stock publicly traded?

Yes, Vir Biotechnology, Inc. - Common Stock is publicly traded.

What exchange does Vir Biotechnology, Inc. - Common Stock trade on?

Vir Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vir Biotechnology, Inc. - Common Stock?

The ticker symbol for Vir Biotechnology, Inc. - Common Stock is VIR on the Nasdaq Stock Market

What is the current price of Vir Biotechnology, Inc. - Common Stock?

The current price of Vir Biotechnology, Inc. - Common Stock is 10.00

When was Vir Biotechnology, Inc. - Common Stock last traded?

The last trade of Vir Biotechnology, Inc. - Common Stock was at 05/01/26 04:00 PM ET

What is the market capitalization of Vir Biotechnology, Inc. - Common Stock?

The market capitalization of Vir Biotechnology, Inc. - Common Stock is 1.34B

How many shares of Vir Biotechnology, Inc. - Common Stock are outstanding?

Vir Biotechnology, Inc. - Common Stock has 1B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.